More on MRK

- Summary
- Chart
- Profile
- Historical


- Earnings (-6.7% Growth)
- Ratings (7.1 Score)
- Holders
- Dividends (3.3% Yield)
- Event Driven Deals
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/2/21 *Est.)
- M&A (6/30/19 *Est)
- M&A (6/30/21 *Est)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

MRK Balance Sheet

Click line-items for a historical chart and %
Current Assets
Cash and cash equivalents 6.63B
Short-term investments 293.1M
Accounts receivable (including non-trade receivables of $571.0 in 2009 and $871.2 in 2008) 3.28B
Inventories (excludes inventories of $846.7 in 2009 and $587.3 in 2008 classified in Other assets - see Note 8) 2.15B
Deferred income taxes and other current assets 2.1B
Total current assets 15.49B
Investments 430.3M
Property, Plant and Equipment, at cost, net of allowance for depreciation of $12,358.0 in 2009 and $12,128.6 in 2008 11.65B
Goodwill 1.44B
Other Intangibles, Net 523.2M
Other Assets 5.15B
Total Assets 41.75B
Current Liabilities
Loans payable and current portion of long-term debt 450.5M
Trade accounts payable 646.8M
Accrued and other current liabilities 5.48B
Income taxes payable 583.7M
Dividends payable 0
Total current liabilities 8.02B
Long-Term Debt 8.07B
Deferred Income Taxes and Noncurrent Liabilities
Merck & Co., Inc. Stockholders' Equity
Common stock, one cent par value Authorized - 5,400,000,000 shares Issued - 2,983,508,675 shares
Other paid-in capital
Retained earnings 37.64B
Accumulated other comprehensive loss -2.57B
Stockholders' equity before deduction for treasury stock 43.76B
Less treasury stock, at cost 874,330,563 shares at September 30, 2009 875,818,333 shares at December 31, 2008 0
Total Merck & Co., Inc. stockholders' equity 15.87B
Noncontrolling Interests 2.41B
Total Equity 18.28B
Total Liabilities and Stockholders' Equity 41.75B